Please login to the form below
Myovant Sciences
This page shows the latest Myovant Sciences news and features for those working in and with pharma, biotech and healthcare.
Takeda forms new women's health and cancer company
Myovant Sciences will focus on delivering innovative therapies in the two areas, with former Medivation chief medical officer Lynn Seely appointed to lead the business. ... For its tie-up with Takeda, the Japanese firm has granted Myovant Sciences an
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Featured jobs
- Digital Associate Director - Medcomms
-
£65000 - £80000 per annum
- Client Services Director - Digital MedComms
-
£60000 - £80000 per annum, Benefits: Pension, healthcare, dedicated training budget, regul
-
Account Manager
-
£Competitive Salary
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
-
Account Director, Medical Education
-
Salary TBC
-
Senior External Communications Lead
-
£Competitive Salary
-
Account Manager (PR)
-
Great Benefits
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
-
Account director
-
Competitive salary and bonus scheme
-
Scientific Director
-
£60000 - £85000 per annum, Benefits: Bonus, pension, subsidised gym and much more
- Senior Medical Writer or Lead Medical Writer
-
£Competitive Salary
- Brand Manager - Medium Global Pharma Company
-
£Competitive Financial Package
- Account Director, Healthcare Communications
-
Salary TBC
-
Account Director
-
£Competitive Salary
- Senior Medical Writer, MedComms Agency
-
Salary TBC
-
Publications director
-
Competitive salary and bonus scheme
Subscribe to our email news alerts
- Novartis faces criticism over Zolgensma ‘health lottery’
- Genital herpes vaccine candidate heads for human studies
- Botox strength bolsters Allergan ahead of AbbVie takeover
- AZ revenues rise, but it says coronavirus could hit 2020
- A market-adapted agile approach to launch excellence
- Novartis pulls ahead of Merck in MET-positive lung cancer race
- SMC enables access to Kyowa Kirin’s Crysvita for rare bone disease
- US states reject drug distributors’ opioid settlement
- BMS unveils long-term results for Opdivo in kidney cancer
- Enabling market access through outcomes-based pricing
- Roche’s PD-L1 inhibitor Tecentriq approved in China for SCLC
- After FDA refusal, Takeda builds case for subcutaneous Entyvio
No results were found
PMHub
Anthill Agency
Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...
Latest intelligence
- Enabling market access through outcomes-based pricing
- Outcomes-based pricing is a potential solution to create a link between product price and real-world outcomes, while at the same time facilitating patient access to new and innovative medicines....
- 20 for 2020 – Five pharma companies to watch
- As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
- The growing clinical importance of patient-reported outcomes (PROs)
- Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...
Quick links
Infographics
